Patient infected with HIV despite long-term adherence to PrEP

February 2, 2017

(HealthDay)—In a letter to the editor published in the Feb. 2 issue of the New England Journal of Medicine, authors present the case of a Canadian man infected with HIV despite long-term adherence to pre-exposure prophylaxis (PrEP).

Based on a of the virus, it was determined that the 43-year-old Toronto resident was infected with a strain of HIV that had become resistant to emtricitabine and tenofovir disoproxil fumarate (Truvada), report author David Knox, M.D., of the Maple Leaf Medical Clinic in Toronto, told HealthDay.

The patient began taking oral Truvada in April 2013. Pharmacy records show he had been taking the drug as prescribed, Knox and colleagues noted. But after two years of successful PrEP, a screening test revealed that the man had contracted HIV. The man was not using condoms during sex, Knox noted, which is recommended for complete protection against HIV, even for patients taking PrEP. However, the man also did not have any other .

"We should be monitoring the rates of these mutations that are occurring in individuals with HIV, and we should be vigilant for unique cases in PrEP users," Knox said. "There's tens of thousands of people who are believed to be on HIV PrEP, and there have been only two documented cases of people who were infected with drug-resistant strains of HIV. I wouldn't use this case as a reason to stop taking PrEP or to dissuade anybody from initiating PrEP if they are at high risk for HIV."

Several authors disclosed financial ties to pharmaceutical companies, including Gilead, the manufacturer of Truvada.

Explore further: CDC guidelines for HIV prevention regimen may not go far enough, study suggests

More information: Full Text

Related Stories

Preventive HIV treatment shown effective at health clinics

November 17, 2015

(HealthDay)—Real-world application of pre-exposure prophylaxis (PrEP) medications appears to be effective for the prevention of HIV, but racial discrepancies exist, new research suggests. The studies appear online Nov. ...

Protection against HSV-2 is added benefit of tenofovir

July 2, 2014

(HealthDay)—Tenofovir for HIV-1 preexposure prophylaxis (PrEP) provides the added benefit of protection against herpes simplex virus type 2 (HSV-2) acquisition, according to a study published in the July 1 issue of the ...

Daily PrEP prevents HIV infection in high-risk individuals

September 4, 2015

(HealthDay)—None of 657 patients who took a daily pill to prevent HIV infection contracted the virus over a period of more than two years, according to a study from Kaiser Permanente of San Francisco. The findings, published ...

Study finds effect of PrEP on bone density is reversible

February 24, 2016

The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers ...

Recommended for you

Scientists zoom in on AIDS virus hideout

March 15, 2017

French scientists said Wednesday they had found a way to pinpoint elusive white blood cells which provide a hideout for the AIDS virus in people taking anti-HIV drugs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.